Allarity shares jump 10.26% premarket after Phase 2 trial shows Stenoparib's median overall survival surpasses 25 months.

Allarity Therapeutics, Inc. surged 10.26% in premarket trading following the CEO’s statement that 2026 represents an “inflection point” for the company. This announcement, highlighted in a recent TipRanks report, signaled optimism about strategic advancements and clinical progress, particularly for its Stenoparib candidate. While prior updates—such as Phase 2 clinical data showing median overall survival exceeding 25 months and FDA Fast Track designation—have historically supported the stock, the immediate catalyst appears to be the CEO’s forward-looking guidance, which reinforced investor confidence in the company’s growth trajectory.